arrow
L

Liza Lindenberg

National Cancer Institute
H指数:28
被引数:2,690

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer

安全性、剂量测定及[68Ga]Ga-PSMA-R2作为成像剂在生化复发或转移性前列腺癌患者中的可行性

2025-02-061
OA
A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

一项关于达鲁珠单抗、卡非佐米和地塞米松(DKd)在高危冒烟型多发性骨髓瘤患者中的2期适应性研究

BLOOD
IF23.1
2024-11-050
PRE
PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)

前列腺癌生化复发(BCR)且未接受雄激素剥夺治疗(ADT)的患者在免疫疗法后的PSA应答和PSMA扫描变化

2024-09-010
PRE
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2024-06-205
OAAI
Deep Learning-Based Detection and Classification of Bone Lesions on Staging Computed Tomography in Prostate Cancer: A Development Study

基于深度学习的前列腺癌分期ct骨病变检测与分类的发展研究

2024-06-010
PRE
Reducing False-Positives Due to Urinary Stagnation in the Prostatic Urethra on 18F-DCFPyL PSMA PET/CT With MRI

通过MRI在18F-DCFPyL PSMA PET/CT上减少由于前列腺尿道中的尿停滞而导致的假阳性

2024-04-191
PRE
Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [177Lu]Lu-DOTA-TATE therapy
2023-10-112
OAAI
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

使用177lu标记的PSMA靶向放射配体疗法 (177Lu-PSMA-RLT) 的EANM/SNMMI联合程序指南

2023-05-2982
OAAI
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
2023-01-05136
OAAI